What is BioSkryb?
Based in Durham, North Carolina, BioSkryb Genomics operates at the intersection of molecular biology and high-throughput sequencing. The company has developed the Primary Template-directed Amplification (PTA) system, a breakthrough technology designed to address the limitations of traditional whole genome amplification. By providing superior coverage breadth and uniformity for low-input sequencing applications, BioSkryb enables researchers to derive high-quality genetic insights from samples that were previously considered too limited for reliable analysis. This technical edge positions the company as a vital infrastructure provider for clinical research and precision medicine initiatives.
The firm's commitment to technical excellence is matched by its strategic focus on reproducibility, a key requirement for the adoption of genomic tools in diagnostic and therapeutic development. By streamlining the sequencing library generation process, BioSkryb is effectively lowering the barrier to entry for complex genetic studies, thereby accelerating the pace of discovery in oncology, reproductive health, and rare disease research.
How much funding has BioSkryb raised?
BioSkryb has raised a total of $11.5M across 1 funding round:
Angel/Seed
$11.5M
Angel/Seed (2020): $11.5M with participation from Anzu Partners and Wilson Sonsini Goodrich & Rosati
Key Investors in BioSkryb
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing $1 billion in assets.
Wilson Sonsini Goodrich & Rosati
A premier legal and advisory firm specializing in the representation of technology, life sciences, and growth enterprises.
What's next for BioSkryb?
With this major enterprise-level funding, BioSkryb is well-positioned to accelerate its commercialization strategy and broaden the application of its PTA technology. The company is expected to prioritize the expansion of its product portfolio, targeting deeper integration into clinical workflows and high-volume laboratory environments. Furthermore, the capital will likely support the scaling of its operational infrastructure to meet the growing global demand for high-fidelity genomic data. As the company matures, its focus will shift toward establishing strategic partnerships with major sequencing platforms and diagnostic providers, solidifying its role as a foundational player in the next generation of genomic analysis.
See full BioSkryb company page
